Home » Topics » BioWorld Science

BioWorld Science
RSS

Diamyd Medical presents 30-month results from phase IIa EDCR study

April 16, 2019

FDA gives clearance to initiate phase II/III study of ARO-AAT for AATD liver disease

April 16, 2019

Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS

April 16, 2019

Shenyang Pharmaceutical University patents neuraminidase inhibitors

April 16, 2019

RTI-1092663 improves metabolic syndrome in mice

April 16, 2019

S100B SNPs and haplotypes as markers of acute and chronic pain in sickle cell disease

April 16, 2019

Preclinical characterization of PF-06882961

April 16, 2019

Synapse formation important for ketamine durability

April 16, 2019

Clinical program update on ADVM-022 gene therapy

April 16, 2019

Alnylam initiates global phase III pediatric ILLUMINATE-B study

April 16, 2019

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...